The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Clinical Inertia in People With Type 2 Diabetes
Open accessAbstract
OBJECTIVE: To determine time to treatment intensification in people with type 2 diabetes treated with one, two, or three oral antidiabetes drugs (OADs) and associated levels of glycemic control. RESEARCH DESIGN AND METHODS: This was a retrospective cohort study based on 81,573 people with type 2 diabetes in the U.K. Clinical Practice Research Datalink between January 2004 and December 2006, with follow-up until April 2011. RESULTS: In people with HbA1c ≥7.0, ≥7.5, or ≥8.0% (≥53, ≥58, or ≥64 mmol/mol), median time from above HbA1c cutoff to intensification with an additional OAD was 2.9, 1.9, or 1.6 years, respectively, for those taking one OAD and >7.2, >7.2, and >6.9 years for those taking two OADs. Median time to intensification with insulin was >7.1, >6.1, or 6.0 years for those taking one, two, or three OADs. Mean HbA1c at intensification with an OAD or insulin for people taking one, two, or three OADs was 8.7, 9.1, and 9.7%. In patients taking one, two, or three OADs, median time from treatment initiation to intensification with an OAD or insulin exceeded the maximum follow-up time of 7.2 years. The probability of patients with poor glycemic control taking one, two, or three OADs, intensifying at end of follow-up with an OAD, was 21.1–43.6% and with insulin 5.1–12.0%. CONCLUSIONS: There are delays in treatment intensification in people with type 2 diabetes despite suboptimal glycemic control. A substantial proportion of people remain in poor glycemic control for several years before intensification with OADs and insulin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Standards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Gerstein, H. C., Miller, M., & Byington, R. P. (2010) · Cited by 981
Resistance to Insulin Therapy Among Patients and Providers
Peyrot, M., Rubin, R. R., Lauritzen, T., Skovlund, S. E., Snoek, F. J., Matthews, D. R., Landgraf, R., Kleinebreil, L., & Panel, O. B. O. T. I. D. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2673 · Cited by 783
A note on competing risks in survival data analysis
Satagopan, J. M., Ben-Porat, L., Berwick, M., Robson, M., Kutler, D., & Auerbach, A. D. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602102 · Cited by 745
Validity of diagnostic coding within the General Practice Research Database: a systematic review
Khan, N. F., Harrison, S. E., & Rose, P. W. (2010) · British Journal of General Practice · doi:10.3399/bjgp10x483562 · Cited by 685
[Management of hyperglycaemia in type 2 diabetes: a patient-centered approach].
Scheen, A. J., & Mathieu, C. (2012) · PubMed · Cited by 581
Use of the UK General Practice Research Database for pharmacoepidemiology
García Rodríguez, L. A., & Pérez Gutthann, S. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00701.x · Cited by 558
Competing Risks: A Practical Perspective
Pintilie, M. (2006) · Cited by 443
The Burden of Treatment Failure in Type 2 Diabetes
Brown, J. B., Nichols, G. A., & Perry, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.7.1535 · Cited by 424
Ceriello, A., Ihnat, M. A., & Thorpe, J. E. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1824 · Cited by 413
Clinical Inertia in Response to Inadequate Glycemic Control
Shah, B. R., Hux, J. E., Laupacis, A., Zinman, B., & van Walraven, C. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.600 · Cited by 388
Competing Risks: A Practical Perspective
Pintilie, M. (2006) · Wiley eBooks · doi:10.1002/9780470870709 · Cited by 364
Grant, R., Adams, A. S., Trinacty, C. M., Zhang, F., Kleinman, K., Soumerai, S. B., Meigs, J. B., & Ross-Degnan, D. (2007) · Diabetes Care · doi:10.2337/dc06-2170 · Cited by 218
Mortality in people with Type 2 diabetes in the UK
Mulnier, H. E., Seaman, H. E., Raleigh, V. S., Soedamah‐Muthu, S. S., Colhoun, H. M., & Lawrenson, R. A. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01838.x · Cited by 212
Clinical Inertia Contributes to Poor Diabetes Control in a Primary Care Setting
Ziemer, D. C., Miller, C. D., Rhee, M. K., Doyle, J. P., Watkins, C., Cook, C. B., Gallina, D. L., El-Kebbi, I. M., Barnes, C. S., Dunbar, V. G., et al. (2005) · The Diabetes Educator · doi:10.1177/0145721705279050 · Cited by 208
Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude
WALLACE, T. M. (2000) · QJM · doi:10.1093/qjmed/93.6.369 · Cited by 166
Rubino, A., McQuay, L. J., Gough, S. C. L., Kvasz, M., & Tennis, P. S. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02279.x · Cited by 155
Home, P., Naggar, N. E., Khamseh, M. E., González-Gálvez, G., Shen, C., Chakkarwar, P., & Wenying, Y. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.021 · Cited by 149
Delay Of Insulin Addition To Oral Combination Therapy Despite Inadequate Glycemic Control
Nichols, G. A., Koo, Y. H., & Shah, S. N. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-007-0139-y · Cited by 137
Calvert, M., McManus, R. J., & Freemantle, N. (2007) · PubMed · Cited by 134
Murray, M. D., Harris, L. E., Overhage, J. M., Zhou, X., Eckert, G. J., Smith, F. E., Buchanan, N. N., Wolinsky, F. D., McDonald, C. J., & Tierney, W. M. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.4.324.33173 · Cited by 131
Clinical inertia in management of T2DM
Zafar, A., Davies, M. J., Azhar, A., & Khunti, K. (2010) · Primary care diabetes · doi:10.1016/j.pcd.2010.07.003 · Cited by 96
Self-citationValensi, P. E., Benroubi, M., Borzì, V., Gumprecht, J., Kawamori, R., Shában, J., Shah, S., Shestakova, M. V., Wenying, Y., & on behalf of the IMPROVE™ Study Group Expert Panel (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01917.x · Cited by 86
Multidrug Treatment of Type 2 Diabetes
Miccoli, R., Penno, G., & Prato, S. D. (2011) · Diabetes Care · doi:10.2337/dc11-s235 · Cited by 52
Changing the Treatment Paradigm for Type 2 Diabetes
Prato, S. D., Penno, G., & Miccoli, R. (2009) · Diabetes Care · doi:10.2337/dc09-s314 · Cited by 42
Initiation of Insulin Treatment after 70 Years of Age: Patient Status 2 Years Later
Elgrably, F., Costagliola, D. G., Chwalow, A. J., et al. (1991) · Diabetic Medicine · doi:10.1111/j.1464-5491.1991.tb01699.x · Cited by 27
Sreenan, S., Virkamäki, A., Zhang, K., Hansen, J. B., & on behalf of the PREDICTIVE™ study group (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01939.x · Cited by 26
Research works printed but not linked: 1
- Bond, 2011, SAS code for the estimation and between-group comparison of cumulative incidence functions in competing risks survival analysis, Pharmaceutical Programming, 4, 1, 10.1179/175709311X13141797023422 · doi:10.1179/175709311x13141797023422
Cited by
Chatterjee, S., Khunti, K., & Davies, M. J. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30058-2 · Cited by 2,577
Self-citationDifferentiation of diabetes by pathophysiology, natural history, and prognosis
Skyler, J. S., Bakris, G. L., Bonifacio, E., Darsow, T., Eckel, R. H., Groop, L., Groop, P.-H., Handelsman, Y., Insel, R. A., Mathieu, C., et al. (2017) · Diabetes · doi:10.2337/db16-0806 · Cited by 823
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Chan, J. C. N., Lim, L.-L., Wareham, N. J., Shaw, J. E., Orchard, T. J., Zhang, P., Lau, E. S. H., Eliasson, B., Kong, A. P. S., Ezzati, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32374-6 · Cited by 793
Self-citationCritchley, J. A., Carey, I. M., Harris, T., DeWilde, S., Hosking, F. J., & Cook, D. G. (2018) · Diabetes Care · doi:10.2337/dc18-0287 · Cited by 391
Khunti, K., Davies, M., Majeed, A., Thorsted, B. L., Wolden, M. L., & Paul, S. K. (2015) · Diabetes Care · doi:10.2337/dc14-0920 · Cited by 356
Self-citation
Metadata
- Authors
- Khunti, K., Wolden, M. L., Thorsted, B. L., Andersen, M., & Davies, M. J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-10-15
- Volume
- 36
- Issue
- 11
- Pages
- 3411-3417
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2105744242
- Cited by
- 613
- References
- 35
- FWCI
- 29.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.